Metabolic phenotypes and risk of colorectal cancer: a systematic review and meta-analysis of cohort studies.

Tytuł:: Metabolic phenotypes and risk of colorectal cancer: a systematic review and meta-analysis of cohort studies.
Autorzy:: Goodarzi G; Department of Nutrition, Science and Research Branch, Islamic Azad University, Tehran, Iran.
Mozaffari H; Faculty of Land and Food Systems, University of British Columbia, Vancouver, Canada.
Raeisi T; Department of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
Mehravar F; Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
Razi B; Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Ghazi ML; Department of Exercise Physiology, Central Tehran Branch, Islamic Azad University, Tehran, Iran.
Garousi N; Department of Clinical Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran.
Alizadeh S; Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences (TUMS), Tehran, Tehran Province, Iran.
Janmohammadi P; Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences (TUMS), Tehran, Tehran Province, Iran. .
Źródło:: BMC cancer [BMC Cancer] 2022 Jan 21; Vol. 22 (1), pp. 89. Date of Electronic Publication: 2022 Jan 21.
Typ publikacji:: Journal Article; Meta-Analysis; Systematic Review
Język:: English
Imprint Name(s):: Original Publication: London : BioMed Central, [2001-
MeSH Terms:: Body Weight*
Colorectal Neoplasms/*etiology
Metabolic Diseases/*complications
Obesity/*complications
Obesity, Metabolically Benign/*complications
Adult ; Aged ; Body Mass Index ; Cohort Studies ; Female ; Humans ; Ideal Body Weight ; Male ; Metabolic Diseases/metabolism ; Middle Aged ; Obesity/metabolism ; Obesity, Metabolically Benign/metabolism ; Odds Ratio ; Phenotype ; Risk Assessment ; Risk Factors
References:: Gastroenterology. 2010 Jun;138(6):2029-2043.e10. (PMID: 20420944)
Cancer Causes Control. 2012 Oct;23(10):1599-605. (PMID: 22855257)
Int J Obes (Lond). 2015 Mar;39(3):514-9. (PMID: 25287753)
Oncol Rep. 2017 Mar;37(3):1312-1320. (PMID: 28098913)
J Am Coll Cardiol. 2015 Jan 6;65(1):101-102. (PMID: 25572516)
Cancer Med. 2021 Jan;10(1):220-229. (PMID: 33216467)
J Gastrointest Cancer. 2019 Jun;50(2):221-229. (PMID: 29335847)
Br J Cancer. 2020 Oct;123(8):1336-1344. (PMID: 32728095)
J Clin Endocrinol Metab. 2008 Oct;93(10):4075-9. (PMID: 18682512)
Metabolism. 2019 Aug;97:50-56. (PMID: 31071310)
Tohoku J Exp Med. 2015;235(2):127-34. (PMID: 25746084)
Cancer Epidemiol Biomarkers Prev. 2017 Feb;26(2):155-161. (PMID: 28148595)
J Clin Invest. 2019 Oct 1;129(10):3978-3989. (PMID: 31524630)
PLoS Med. 2016 Apr 05;13(4):e1001988. (PMID: 27046222)
Gut. 2013 Jun;62(6):933-47. (PMID: 23481261)
Medicine (Baltimore). 2015 Oct;94(40):e1705. (PMID: 26448024)
World J Gastroenterol. 2015 May 7;21(17):5167-75. (PMID: 25954090)
Eur J Clin Invest. 2014 Nov;44(11):1053-64. (PMID: 25231836)
Ann Epidemiol. 2004 Sep;14(8):585-91. (PMID: 15350959)
Int J Cancer. 2018 Aug 1;143(3):543-551. (PMID: 29488210)
Eur J Intern Med. 2016 Oct;34:89-93. (PMID: 27545645)
J Am Coll Cardiol. 2010 Sep 28;56(14):1113-32. (PMID: 20863953)
BMJ. 2021 Mar 29;372:n71. (PMID: 33782057)
Int J Obes (Lond). 2012 Mar;36(3):440-7. (PMID: 21673650)
Cancer Epidemiol Biomarkers Prev. 2014 Oct;23(10):2057-65. (PMID: 25012997)
Int J Obes (Lond). 2017 Jan;41(1):170-177. (PMID: 27748744)
Physiol Genomics. 2016 Aug 1;48(8):545-53. (PMID: 27317588)
BMC Med Res Methodol. 2014 Apr 01;14:45. (PMID: 24690082)
Mol Endocrinol. 2011 Jun;25(6):969-79. (PMID: 21493669)
Recent Results Cancer Res. 2016;208:17-41. (PMID: 27909900)
Dis Colon Rectum. 2017 Nov;60(11):1192-1200. (PMID: 28991084)
Clin Nutr. 2017 Oct;36(5):1301-1309. (PMID: 27665232)
Eur J Endocrinol. 2015 Nov;173(5):703-8. (PMID: 26286585)
Nature. 2007 Oct 18;449(7164):913-8. (PMID: 17943131)
Curr Nutr Rep. 2013 Mar;2(1):1-9. (PMID: 23396857)
World J Diabetes. 2019 Jun 15;10(6):350-361. (PMID: 31231458)
Int J Endocrinol Metab. 2018 Mar 12;16(2):e60048. (PMID: 30008758)
Arch Endocrinol Metab. 2019 Jul 29;63(4):427-437. (PMID: 31365625)
Endocrine. 2019 Mar;63(3):439-462. (PMID: 30671787)
J Hum Hypertens. 2019 May;33(5):365-377. (PMID: 30568291)
CA Cancer J Clin. 2020 May;70(3):145-164. (PMID: 32133645)
Cancer Res. 2008 Oct 1;68(19):8004-13. (PMID: 18829558)
Obes Rev. 2020 Oct;21(10):e13049. (PMID: 32476278)
Clin Nutr. 2020 Oct;39(10):2975-2981. (PMID: 32063407)
Adv Clin Chem. 2010;51:71-119. (PMID: 20857619)
J Clin Endocrinol Metab. 2020 Mar 1;105(3):. (PMID: 31967306)
Contributed Indexing:: Keywords: Colorectal cancer; Obesity; Phenotypes
Entry Date(s):: Date Created: 20220122 Date Completed: 20220302 Latest Revision: 20231105
Update Code:: 20240105
PubMed Central ID:: PMC8781040
DOI:: 10.1186/s12885-021-09149-w
PMID:: 35062912
: Czasopismo naukowe

Pełny tekst

Background: The association of obesity with colorectal cancer (CRC) may vary depending on metabolic status.
Objective: This meta-analysis aimed to investigate the combined impacts of obesity and metabolic status on CRC risk.
Methods: The Scopus, PubMed, and web of sciences databases were systematically searched up to Jun 2021 to find all eligible publications examining CRC risk in individuals with metabolically unhealthy normal-weight (MUHNW), metabolically healthy obesity (MHO), and metabolically unhealthy obesity (MUHO) phenotypes.
Results: A total of 7 cohort studies with a total of 759,066 participants were included in this meta-analysis. Compared with healthy normal-weight people, MUHNW, MHO, and MUHO individuals indicated an increased risk for CRC with a pooled odds ratio of 1.19 (95% CI = 1.09-1.31) in MUHNW, 1.14 (95% CI = 1.06-1.22) in MHO, and 1.24 (95% CI = 1.19-1.29) in MUHO subjects. When analyses were stratified based on gender, associations remained significant for males. However, the elevated risk of CRC associated with MHO and MUHO was not significant in female participants.
Conclusions: The individuals with metabolic abnormality, although at a normal weight, have an increased risk for CRC. Moreover, obesity is associated with CRC irrespective of metabolic status.
(© 2022. The Author(s).)

Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Informacja